Please login to the form below

Not currently logged in
Email:
Password:

Teva appoints genetics specialist as its first president of global R&D

Michael Hayden will also serve as chief scientific officer at the generics company

Michael Hayden - Teva PharmaceuticalTeva Pharmaceutical has appointed genetics expert Dr Michael Hayden as its first president of global R&D and chief scientific officer.

The move shows further research ambitions for the traditionally generics-focused company, with Dr Hayden to lead the development of both branded and generic medicines.

Dr Hayden's extensive background in genetics is likely to be important for Teva too, considering the industry's increasing interest in personalised medicines.

His experience in the field includes current roles as Killam Professor of Medical Genetics at the University of British Columbia, Canada, and Canada research chair in human genetics and molecular medicine as part of a government-supported programme.

He is also the founder and director of the centre for molecular medicine and therapeutics at the University of British Columbia.

In addition, Dr Hayden has experience within the biopharma industry, having founded the biotech companies NeuroVir, Aspreva Pharmaceuticals and Xenon Genetics.

Dr Jeremy Levin, who is set to replace Shlomo Yania as Teva's president and CEO, said: “We are delighted to have Michael join us as our chief scientific officer. He brings to Teva world-renowned experience and knowledge in scientific and clinical research coupled with deep knowledge of discovery and development of medicines.”

10th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics